极目峰睿（上海）生物科技有限公司 Arctic Vision
{{company.company_channel.channel_name}}
Media Room
{{company.company_name_local}}
{{company.company_channel.channel_name}}
Company Profile
Media Room
Arctic Vision Announces First Patient Enrolled in Phase III Clinical Trial of ARVN003 for Presbyopia 2022-07-04 22:14
Arctic Vision Announces First Patient Dosed in Phase III Study of ARVN001 for Treatment of Macular Edema Associated with Uveitis (UME) 2021-11-22 23:17
Arctic Vision Announces Addition of Novel Mydriatic Drug MydCombi™ (ARVN004) to Eyenovia Commercialization Deal 2021-09-17 08:00
Arctic Vision Obtains China IND Clearance for Phase III Study of ARVN003, the First in China for Presbyopia Treatment 2021-09-03 08:00
Arctic Vision Announces Expansion of License Territory for Suprachoroidal Space Injection Therapy ARVN001 to Include ASEAN Countries and India 2021-08-16 08:00
Arctic Vision Joins Forces with the University of Hong Kong Department of Ophthalmology to Discover and Develop Novel Neuroprotective Therapies for Ocular Disease 2021-07-05 08:00
Arctic Vision Announces Exclusive Licensing Agreement with Olympic Ophthalmics for iTEAR®100 for the Treatment of Dry Eye Disease in Greater China, South Korea and ASEAN countries 2021-06-07 08:00
Arctic Vision announces exclusive licensing agreement with ActualEyes 2021-05-14 20:00
Arctic Vision Announces Completion of Over US$100 Million Series B Financing to Accelerate Portfolio Expansion, Clinical Development and Commercialization 2021-03-10 08:00
Arctic Vision obtains the first IND approval for the treatment of UME in China, Suprachoroidal space (SCS) injection potentially brings more benefits to patients 2020-12-25 21:00
Arctic Vision Announces US$32MN in Series A to Expand and Develop Innovative Therapies Pipeline in Ophthalmology 2020-07-14 09:30
1